Combining Vyvanse with Qelbree: Safety and Clinical Considerations
Combining Vyvanse (lisdexamfetamine) with Qelbree (viloxazine extended-release) is safe and can be done without dose adjustment for either medication, based on pharmacokinetic studies showing no clinically significant drug-drug interactions. 1
Pharmacokinetic Evidence
The combination has been specifically studied in healthy adults, demonstrating that co-administration does not meaningfully alter the pharmacokinetics of either drug 1:
- Viloxazine exposure when combined with lisdexamfetamine: Cmax 95.96%, AUC 99.19% (essentially unchanged)
- D-amphetamine exposure (active metabolite of lisdexamfetamine) when combined with viloxazine: Cmax 112.78%, AUC 109.64% (minimal increase, not clinically significant)
The slight increase in amphetamine exposure (~10%) falls well within normal pharmacokinetic variability and does not require dose adjustment.
Clinical Experience in Pediatric ADHD
A phase 4 open-label trial evaluated this combination in 56 children and adolescents (ages 6-17) with inadequate response to psychostimulant monotherapy 2:
- Safety profile: Well tolerated with only 3.6% discontinuing due to adverse events
- Common adverse events: Headache (17.9%), decreased appetite (12.5%), upper respiratory infection (10.7%)
- Efficacy: ADHD-RS-5 scores improved by -18.2 points at week 8 (p<0.0001)
- Completion rate: 85.7% completed the 8-week study
Monitoring Recommendations
While the combination is safe, monitor for:
Cardiovascular effects:
- Heart rate and blood pressure (both medications can increase these parameters)
- The combination does not produce additive cardiovascular effects beyond what would be expected from either medication alone 1
Common overlapping side effects:
- Decreased appetite (occurs with both medications)
- Insomnia (particularly with stimulants)
- Headache
Drug interaction considerations: Viloxazine is a strong CYP1A2 inhibitor and weak CYP2D6 and CYP3A4 inhibitor 3, 4. However, lisdexamfetamine is not metabolized by these pathways—it is converted to d-amphetamine by red blood cell hydrolysis—so no interaction occurs via this mechanism.
Practical Prescribing Approach
When to consider combination therapy:
- Inadequate response to stimulant monotherapy (defined as ADHD-RS-5 ≥24 and CGI-S ≥3) 2
- Need for extended symptom coverage throughout the day
- Desire to minimize stimulant dose while maintaining efficacy
Dosing strategy:
- Optimize the stimulant dose first during a 4-week trial
- If response remains inadequate, add viloxazine ER starting at 200 mg/day
- Titrate viloxazine flexibly between 200-600 mg/day based on response and tolerability
- No adjustment needed to the lisdexamfetamine dose
Timing considerations: Viloxazine can be dosed morning or evening without affecting efficacy or sleep outcomes 2. Choose timing based on individual tolerability (e.g., evening dosing if daytime somnolence occurs).
Important Contraindications
The Qelbree label specifically contraindications concomitant use with MAOIs (risk of hypertensive crisis) 3. However, no contraindication exists for combining with stimulants like lisdexamfetamine.
Rationale for Combination
This combination follows established principles for ADHD medication combinations 5:
- Treats a single disorder with complementary mechanisms (stimulant + non-stimulant)
- Viloxazine's serotonin-norepinephrine modulating effects complement lisdexamfetamine's dopamine-norepinephrine effects
- May provide benefits for executive function and emotional regulation beyond core ADHD symptoms 2
The combination is not combining two medications from the same class (which has limited evidence in pediatrics 5), but rather using complementary mechanisms to optimize treatment response.